$AVR

L1 Capital Pty Ltd sold $187K of AVR (indirect holdings)

L1 Capital Pty Ltd sold 23,000 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $8.13 ($0.19M total) on 2026-07-24.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 28, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The newest concrete fact is the reported open-market sale size, price, and post-transaction share count, which may influence short-term sentiment but does not introduce new operating or regulatory information.

02

Market read

Traders may monitor for follow-on insider activity or changes in ownership, but the filing alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The article does not provide context for why the sale occurred (taxes, diversification, estate planning) and does not include any concurrent buy/sell by other insiders or changes in company outlook.

Relevance 4/10Novelty 4/10Timing: after-hours filing timestamp on 2026-07-28 for a 2026-07-24 sale

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, filed a Form 4 showing an indirect open-market sale of 23,000 shares at $8.13 on 2026-07-24.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but the article includes no new company-specific catalyst, and it states no 10b5-1 plan.

Market effects

No sector read-across; this is a single issuer insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management by a large holder, especially since the filing is for an indirect position and does not cite any company-specific issue.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure (ticker AVR).

  • L1 Capital Pty Ltd

    Reporter of the Form 4, selling 23,000 shares indirectly at $8.13 on 2026-07-24.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.